In most of MM patients, CD38 was found positive and several anti-CD38 mAbs have been screened out to enter the clinical trials; in CLL cells, CD38 was also considered to form a complex network delivering survival signals, which made CD38 an attractive target for CLL therapy. This evidence concerns the gene CD38 and Miyoshi myopathy.